



## Clinical trial results:

### A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

#### Summary

EudraCT number	2015-001644-11
Trial protocol	SE GB BE DK DE FR
Global end of trial date	24 April 2020

#### Results information

Result version number	v2 (current)
This version publication date	23 June 2021
First version publication date	06 November 2020
Version creation reason	<ul style="list-style-type: none"><li>• New data added to full data set</li><li>Addition of Secondary Endpoints</li></ul>

#### Trial information

##### Trial identification

Sponsor protocol code	VX15-809-110
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02544451
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States,
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001582-PIP01-13
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 August 2018
Global end of trial reached?	Yes
Global end of trial date	24 April 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the long term safety and tolerability of lumacaftor (LUM) in combination with ivacaftor (IVA) in subjects aged 6 years and older with cystic fibrosis (CF), homozygous for the F508del CFTR mutation, who are in the Treatment Cohort.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 August 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 143
Country: Number of subjects enrolled	Canada: 21
Country: Number of subjects enrolled	Belgium: 14
Country: Number of subjects enrolled	France: 13
Country: Number of subjects enrolled	Germany: 10
Country: Number of subjects enrolled	United Kingdom: 9
Country: Number of subjects enrolled	Denmark: 7
Country: Number of subjects enrolled	Sweden: 1
Country: Number of subjects enrolled	Australia: 28
Worldwide total number of subjects	246
EEA total number of subjects	54

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	225
Adolescents (12-17 years)	21
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study consists of 2 Treatment Periods: Treatment Period 1 and Treatment Period 2. Treatment Period 1 had Treatment Cohorts and an Observational Cohort.

### Pre-assignment

Screening details:

Subjects from Parent Studies 109 (NCT02514473) and 011B (NCT01897233) were enrolled in this study. A total of 240 subjects were enrolled in Treatment Cohort, out of which 1 subject was enrolled but never dosed. Subjects enrolled in the Observational and Treatment Period 2 Cohorts followed for safety endpoints only, no efficacy data were collected.

### Period 1

Period 1 title	Treatment Period 1 (96 Weeks)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	LUM/IVA to LUM/IVA

Arm description:

Subjects received LUM/IVA in parent studies (109, 011B) and continued to receive LUM/IVA for 96 weeks in the current study.

Arm type	Experimental
Investigational medicinal product name	LUM/IVA
Investigational medicinal product code	VX-809/VX-770
Other name	lumacaftor/ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received LUM/IVA twice daily for 96 weeks.

<b>Arm title</b>	PBO to LUM/IVA
------------------	----------------

Arm description:

Subjects received placebo (PBO) in parent study (109) and then received LUM/IVA for 96 weeks in the current study.

Arm type	Experimental
Investigational medicinal product name	LUM/IVA
Investigational medicinal product code	VX-809/VX-770
Other name	lumacaftor/ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received LUM/IVA twice daily for 96 weeks.

<b>Arm title</b>	Observational Cohort
------------------	----------------------

Arm description:

Subjects completed a parent study (109, 011B) but were not eligible or elected to not receive LUM/IVA for 96 weeks in the current study.

Arm type	No intervention
----------	-----------------

<b>Number of subjects in period 1<sup>[1]</sup></b>	LUM/IVA to LUM/IVA	PBO to LUM/IVA	Observational Cohort
Started	143	96	6
Completed	129	84	5
Not completed	14	12	1
Physician decision	4	-	-
Adverse Event	1	6	-
Other	4	4	-
Withdrawal of consent	-	-	1
Lost to follow-up	2	-	-
Withdrawal of consent (not due to AE)	3	2	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 240 subjects were enrolled in Treatment Cohort of Treatment Period 1, out of which 1 subject was enrolled but never dosed.

## Period 2

Period 2 title	Treatment Period 2 (168 Weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Treatment period 2: LUM/IVA
------------------	-----------------------------

Arm description:

Eligible subjects from Treatment Period 1 received LUM/IVA for up to approximately 168 weeks.

Arm type	Experimental
Investigational medicinal product name	LUM/IVA
Investigational medicinal product code	VX-809/VX-770
Other name	lumacaftor/ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received LUM/IVA twice daily for 168 weeks.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Treatment period 2: LUM/IVA
Started	10
Completed	0
Not completed	10
Commercial drug is available for subject	10

---

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only eligible subjects from Treatment Period 1 received LUM/IVA during optional Treatment Period 2.

## Baseline characteristics

### Reporting groups

Reporting group title	LUM/IVA to LUM/IVA
Reporting group description:	
Subjects received LUM/IVA in parent studies (109, 011B) and continued to receive LUM/IVA for 96 weeks in the current study.	
Reporting group title	PBO to LUM/IVA
Reporting group description:	
Subjects received placebo (PBO) in parent study (109) and then received LUM/IVA for 96 weeks in the current study.	
Reporting group title	Observational Cohort
Reporting group description:	
Subjects completed a parent study (109, 011B) but were not eligible or elected to not receive LUM/IVA for 96 weeks in the current study.	

Reporting group values	LUM/IVA to LUM/IVA	PBO to LUM/IVA	Observational Cohort
Number of subjects	143	96	6
Age categorical			
Units: Subjects			
Less than 9 Years	58	38	5
Greater than or equal to 9 years	85	58	1
Gender categorical			
Units: Subjects			
Female	83	56	2
Male	60	40	4
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	2	2	0
Not Hispanic or Latino	139	93	6
Unknown or Not Reported	2	1	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	140	92	6
More than one race	0	0	0
Unknown or Not Reported	3	3	0

Reporting group values	Total		
Number of subjects	245		
Age categorical			
Units: Subjects			
Less than 9 Years	101		
Greater than or equal to 9 years	144		

Gender categorical Units: Subjects			
Female	141		
Male	104		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	4		
Not Hispanic or Latino	238		
Unknown or Not Reported	3		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0		
Asian	1		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	238		
More than one race	0		
Unknown or Not Reported	6		



## End points

### End points reporting groups

Reporting group title	LUM/IVA to LUM/IVA
Reporting group description: Subjects received LUM/IVA in parent studies (109, 011B) and continued to receive LUM/IVA for 96 weeks in the current study.	
Reporting group title	PBO to LUM/IVA
Reporting group description: Subjects received placebo (PBO) in parent study (109) and then received LUM/IVA for 96 weeks in the current study.	
Reporting group title	Observational Cohort
Reporting group description: Subjects completed a parent study (109, 011B) but were not eligible or elected to not receive LUM/IVA for 96 weeks in the current study.	
Reporting group title	Treatment period 2: LUM/IVA
Reporting group description: Eligible subjects from Treatment Period 1 received LUM/IVA for up to approximately 168 weeks.	
Subject analysis set title	LCI Set: LUM/IVA to LUM/IVA
Subject analysis set type	Sub-group analysis
Subject analysis set description: All subjects in the LCI set who received LUM/IVA in the parent study (109 or 011B LCI sub-study).	
Subject analysis set title	LCI Set: PBO to LUM/IVA
Subject analysis set type	Sub-group analysis
Subject analysis set description: All subjects in the LCI set who received PBO in the parent study (109).	
Subject analysis set title	FAS: LUM/IVA to LUM/IVA
Subject analysis set type	Full analysis
Subject analysis set description: All subjects in the Full Analysis Set (FAS) who received LUM/IVA in the parent study (109, 011 B).	
Subject analysis set title	FAS: PBO to LUM/IVA
Subject analysis set type	Full analysis
Subject analysis set description: All subjects in the FAS who received PBO in the parent study (109).	
Subject analysis set title	LCI: LUM/IVA Overall
Subject analysis set type	Full analysis
Subject analysis set description: All subjects who received LUM/IVA in parent study 109, 011B LCI sub-study, or current study.	
Subject analysis set title	ppFEV1: LUM/IVA Overall
Subject analysis set type	Full analysis
Subject analysis set description: All subjects who received LUM/IVA in either parent study (109, 011 B) or current study.	
Subject analysis set title	Parent Study 109 Set: LUM/IVA to LUM/IVA
Subject analysis set type	Sub-group analysis
Subject analysis set description: All subjects who received LUM/IVA in parent study 109.	
Subject analysis set title	Parent Study 109 Set: PBO to LUM/IVA
Subject analysis set type	Sub-group analysis
Subject analysis set description: All subjects who received PBO in parent study 109.	

## Primary: Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) <sup>[1][2]</sup>
-----------------	--

End point description:

Safety set included all subjects who received at least 1 dose of study drug in Treatment Period 1.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Week 100

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint. Therefore, only descriptive data are provided.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was applicable for Treatment Period 1 Treatment Cohort arms. Therefore, data are reported for these arms only.

End point values	LUM/IVA to LUM/IVA	PBO to LUM/IVA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	143	96		
Units: subjects				
Subjects with any AEs	142	94		
Subjects with SAEs	43	29		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute Change in Lung Clearance Index (LCI) 2.5

End point title	Absolute Change in Lung Clearance Index (LCI) 2.5
-----------------	---

End point description:

LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value. LCI set includes all subjects enrolled and dosed in either parent study 109 or 011B LCI sub-study. Analysis period includes both parent study and current study.

End point type	Secondary
----------------	-----------

End point timeframe:

From Parent Study Baseline at Week 96

End point values	LCI Set: LUM/IVA to LUM/IVA	LCI Set: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	133	101		
Units: lung clearance index				
least squares mean (confidence interval 95%)	-0.85 (-1.25 to -0.45)	-0.86 (-1.33 to -0.38)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Sweat Chloride

End point title	Absolute Change in Sweat Chloride
End point description: Sweat samples were collected using an approved collection device. FAS includes all subjects enrolled and dosed in either parent study. Analysis period includes both parent study and current study.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: millimole per liter (mmol/L)				
least squares mean (confidence interval 95%)	-22.9 (-25.5 to -20.3)	-22.8 (-26.3 to -19.3)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Body Mass Index (BMI)

End point title	Absolute Change in Body Mass Index (BMI)
End point description: BMI was defined as weight in kilograms divided by height in square meter (m <sup>2</sup> ). FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: kg/m <sup>2</sup>				
least squares mean (confidence interval 95%)	1.78 (1.56 to 1.99)	2.04 (1.77 to 2.31)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

End point title	Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
-----------------	---

End point description:

The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Parent Study Baseline at Week 96

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: units on a scale				
least squares mean (confidence interval 95%)	7.4 (4.8 to 10.0)	6.6 (3.1 to 10.0)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)

End point title	Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs) <sup>[3]</sup>
-----------------	--

End point description:

All subjects included in the observational cohort.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Week 100

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was applicable for Treatment Period 1 Observation Cohort arm. Therefore, data are reported for this arm only.

End point values	Observational Cohort			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: subjects	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in LCI 5.0

End point title	Absolute Change in LCI 5.0
End point description: LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value. LCI set.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	LCI Set: LUM/IVA to LUM/IVA	LCI Set: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	133	101		
Units: lung clearance index				
least squares mean (confidence interval 95%)	-0.21 (-0.36 to -0.06)	-0.31 (-0.49 to -0.13)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

End point title	Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
End point description: FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: percent predicted of FEV1				
least squares mean (confidence interval 95%)	3.1 (1.0 to 5.1)	0.0 (-2.7 to 2.7)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Relative Change in ppFEV1

End point title	Relative Change in ppFEV1
End point description: FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: percent change				
least squares mean (confidence interval 95%)	4.9 (2.2 to 7.5)	0.5 (-2.9 to 4.0)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in BMI-for-age Z-score

End point title	Absolute Change in BMI-for-age Z-score
End point description: BMI was defined as weight in kilograms divided by height in m <sup>2</sup> . z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: z-score				
least squares mean (confidence interval 95%)	0.17 (0.08 to 0.26)	0.31 (0.19 to 0.42)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Weight

End point title	Absolute Change in Weight
End point description: FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: kg				
least squares mean (confidence interval 95%)	10.3 (9.6 to 11.0)	11.0 (10.1 to 11.8)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Weight-for-age Z-score

End point title	Absolute Change in Weight-for-age Z-score
End point description: The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. FAS.	
End point type	Secondary
End point timeframe: From Parent Study Baseline at Week 96	

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: z-score				
least squares mean (confidence interval 95%)	0.12 (0.04 to 0.20)	0.24 (0.14 to 0.34)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Height

End point title	Absolute Change in Height
End point description:	FAS.
End point type	Secondary
End point timeframe:	From Parent Study Baseline at Week 96

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: centimeter (cm)				
least squares mean (confidence interval 95%)	13.4 (12.9 to 14.0)	13.5 (12.8 to 14.1)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Height-for-age Z-score

End point title	Absolute Change in Height-for-age Z-score
End point description:	The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. FAS.
End point type	Secondary
End point timeframe:	From Parent Study Baseline at Week 96



End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: z-score				
least squares mean (confidence interval 95%)	-0.01 (-0.08 to 0.07)	0.02 (-0.07 to 0.11)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score

End point title	Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score
-----------------	--

End point description:

The TSQM measures subjects' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction. FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Parent Study Baseline at Week 96

End point values	FAS: LUM/IVA to LUM/IVA	FAS: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161	101		
Units: units on a scale				
least squares mean (confidence interval 95%)	5.1 (1.7 to 8.4)	3.9 (-0.6 to 8.5)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time-to-first Pulmonary Exacerbation

End point title	Time-to-first Pulmonary Exacerbation
-----------------	--------------------------------------

End point description:

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Analysis included all subjects dosed in parent study 109. LUM/IVA to LUM/IVA analysis period includes both

parent study and current study. PBO to LUM/IVA analysis period includes the current study only. Here, 99999 represents "Not Estimable" as the upper limit of inter-quartile range could not be estimated for LUM/IVA to LUM/IVA arm because less than 75% of subjects had events and median and upper limit of inter-quartile range could not be estimated for PBO to LUM/IVA because less than 50% of subjects had events.

End point type	Secondary
End point timeframe:	
From Parent Study Baseline through Week 96	

End point values	Parent Study 109 Set: LUM/IVA to LUM/IVA	Parent Study 109 Set: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	103	96		
Units: days				
median (inter-quartile range (Q1-Q3))	720.00 (278.00 to 99999)	99999 (513.00 to 99999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects Having At Least 1 Pulmonary Exacerbation Event

End point title	Percentage of Subjects Having At Least 1 Pulmonary Exacerbation Event
-----------------	---

End point description:

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Analysis included all subjects dosed in parent study 109. LUM/IVA to LUM/IVA analysis period includes both parent study and current study. PBO to LUM/IVA analysis period includes the current study only.

End point type	Secondary
End point timeframe:	
From Parent Study Baseline through Week 96	

End point values	Parent Study 109 Set: LUM/IVA to LUM/IVA	Parent Study 109 Set: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	103	96		
Units: percentage of subjects				
number (not applicable)	49.5	32.3		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Pulmonary Exacerbation Events Per Patient-year

End point title	Number of Pulmonary Exacerbation Events Per Patient-year
-----------------	--

End point description:

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Analysis included all subjects dosed in parent study 109. LUM/IVA to LUM/IVA analysis period includes both parent study and current study. PBO to LUM/IVA analysis period includes the current study only.

End point type	Secondary
----------------	-----------

End point timeframe:

From Parent Study Baseline through Week 96

End point values	Parent Study 109 Set: LUM/IVA to LUM/IVA	Parent Study 109 Set: PBO to LUM/IVA		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	103	96		
Units: events per patient-year				
number (confidence interval 95%)	0.45 (0.33 to 0.61)	0.30 (0.21 to 0.43)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Rate of Change in LCI 2.5

End point title	Rate of Change in LCI 2.5
-----------------	---------------------------

End point description:

Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable. As pre-specified in the SAP, this analysis was conducted in the LUM/IVA Overall group because of sample size. Analysis period is 15 days after first dose of LUM/IVA in parent study or current study (if assigned to placebo in study 109) through the end of current study.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 15 after first dose of LUM/IVA through Week 96

<b>End point values</b>	LCI: LUM/IVA Overall			
Subject group type	Subject analysis set			
Number of subjects analysed	229			
Units: slope				
number (confidence interval 95%)	-0.01 (-0.12 to 0.09)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Rate of Change in LCI 5.0

End point title	Rate of Change in LCI 5.0
-----------------	---------------------------

End point description:

Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable. As pre-specified in the SAP, this analysis was conducted in the LUM/IVA Overall group because of sample size. Analysis period is 15 days after first dose of LUM/IVA in parent study or current study (if assigned to placebo in study 109) through the end of current study.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 15 after first dose of LUM/IVA through Week 96

<b>End point values</b>	LCI: LUM/IVA Overall			
Subject group type	Subject analysis set			
Number of subjects analysed	229			
Units: slope				
number (confidence interval 95%)	0.00 (-0.04 to 0.04)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Rate of Change in ppFEV1

End point title	Rate of Change in ppFEV1
-----------------	--------------------------

End point description:

Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable. As pre-specified in the SAP, this analysis was conducted in the LUM/IVA Overall group because of sample size. Analysis period is 15 days after first dose of LUM/IVA in parent study or current study (if assigned to placebo in study 109) through the end of current study.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 15 after first dose of LUM/IVA through Week 96

<b>End point values</b>	ppFEV1: LUM/IVA Overall			
Subject group type	Subject analysis set			
Number of subjects analysed	245 <sup>[4]</sup>			
Units: slope				
number (confidence interval 95%)	0.58 (0.02 to 1.14)			

Notes:

[4] - All subjects who received LUM/IVA in either parent study or current study were 257.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Treatment Period 2: Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Treatment Period 2: Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)			
End point description:	Safety set included all subjects who received at least 1 dose of study drug in Treatment Period 2.			
End point type	Secondary			
End point timeframe:	Day 1 up to Week 168			

<b>End point values</b>	Treatment period 2: LUM/IVA			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: subjects				
Subjects with AEs	9			
Subjects with SAEs	0			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment Period 1: Day 1 up to Week 100

Treatment Period 2: Day 1 up to Week 168

Adverse event reporting additional description:

Only serious adverse events were collected for the observational cohort. Non-serious AEs were not collected and are not reported for the observational cohort. Adverse events reported based on MedDRA version 21.0 for Treatment Period 1 and MedDRA version 22.1 for Treatment Period 2.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0, 22.1
--------------------	------------

### Reporting groups

Reporting group title	Treatment Period 1: LUM/IVA to LUM/IVA
-----------------------	--

Reporting group description:

Subjects received LUM/IVA in parent studies (109, 011B) and continued to receive LUM/IVA for 96 weeks in the current study.

Reporting group title	Treatment Period 1: PBO to LUM/IVA
-----------------------	------------------------------------

Reporting group description:

Subjects received placebo (PBO) in parent study (109) and then received LUM/IVA for 96 weeks in the current study.

Reporting group title	Observational Cohort
-----------------------	----------------------

Reporting group description:

Subjects completed a parent study (109, 011B) but were not eligible or elected to not receive LUM/IVA for 96 weeks in the current study.

Reporting group title	Treatment Period 2: LUM/IVA
-----------------------	-----------------------------

Reporting group description:

Eligible subjects from Treatment Period 1 received LUM/IVA for up to approximately 168 weeks.

Serious adverse events	Treatment Period 1: LUM/IVA to LUM/IVA	Treatment Period 1: PBO to LUM/IVA	Observational Cohort
Total subjects affected by serious adverse events			
subjects affected / exposed	43 / 143 (30.07%)	29 / 96 (30.21%)	1 / 6 (16.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			
Pulmonary function test decreased			
subjects affected / exposed	2 / 143 (1.40%)	2 / 96 (2.08%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical mycobacterium test positive			

subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas test positive			
subjects affected / exposed	1 / 143 (0.70%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 143 (0.00%)	2 / 96 (2.08%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 143 (0.00%)	2 / 96 (2.08%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Intentional overdose			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cystic fibrosis hepatic disease			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystic fibrosis lung			

subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	4 / 143 (2.80%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Distal intestinal obstruction syndrome			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Haemoptysis			



subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus disorder			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	34 / 143 (23.78%)	15 / 96 (15.63%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	1 / 48	1 / 25	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis allergic			
subjects affected / exposed	2 / 143 (1.40%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical mycobacterial lower respiratory tract infection			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection bacterial			

subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 143 (0.70%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetic ketoacidosis			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Treatment Period 2: LUM/IVA		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Investigations			
Pulmonary function test decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical mycobacterium test positive			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oxygen saturation decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pseudomonas test positive			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Intentional overdose			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Cystic fibrosis hepatic disease			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystic fibrosis lung			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Distal intestinal obstruction syndrome			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Autoimmune hepatitis			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Haemoptysis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleuritic pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus disorder			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchopulmonary aspergillosis allergic			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical mycobacterial lower respiratory tract infection			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Diabetic ketoacidosis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Treatment Period 1: LUM/IVA to LUM/IVA	Treatment Period 1: PBO to LUM/IVA	Observational Cohort
Total subjects affected by non-serious adverse events			
subjects affected / exposed	141 / 143 (98.60%)	93 / 96 (96.88%)	0 / 6 (0.00%)
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	45 / 143 (31.47%)	27 / 96 (28.13%)	0 / 6 (0.00%)
occurrences (all)	64	41	0
Fatigue			
subjects affected / exposed	10 / 143 (6.99%)	11 / 96 (11.46%)	0 / 6 (0.00%)
occurrences (all)	14	12	0
Chest pain			
subjects affected / exposed	2 / 143 (1.40%)	5 / 96 (5.21%)	0 / 6 (0.00%)
occurrences (all)	2	5	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	8 / 143 (5.59%)	5 / 96 (5.21%)	0 / 6 (0.00%)
occurrences (all)	13	6	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	91 / 143 (63.64%)	64 / 96 (66.67%)	0 / 6 (0.00%)
occurrences (all)	195	166	0
Nasal congestion			
subjects affected / exposed	34 / 143 (23.78%)	21 / 96 (21.88%)	0 / 6 (0.00%)
occurrences (all)	60	29	0
Oropharyngeal pain			
subjects affected / exposed	32 / 143 (22.38%)	18 / 96 (18.75%)	0 / 6 (0.00%)
occurrences (all)	59	29	0
Rhinorrhoea			
subjects affected / exposed	24 / 143 (16.78%)	13 / 96 (13.54%)	0 / 6 (0.00%)
occurrences (all)	39	18	0
Productive cough			
subjects affected / exposed	19 / 143 (13.29%)	15 / 96 (15.63%)	0 / 6 (0.00%)
occurrences (all)	51	26	0

Sputum increased			
subjects affected / exposed	18 / 143 (12.59%)	7 / 96 (7.29%)	0 / 6 (0.00%)
occurrences (all)	21	7	0
Sinus congestion			
subjects affected / exposed	12 / 143 (8.39%)	4 / 96 (4.17%)	0 / 6 (0.00%)
occurrences (all)	16	5	0
Nasal polyps			
subjects affected / exposed	9 / 143 (6.29%)	3 / 96 (3.13%)	0 / 6 (0.00%)
occurrences (all)	9	4	0
Haemoptysis			
subjects affected / exposed	8 / 143 (5.59%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	10	1	0
Wheezing			
subjects affected / exposed	8 / 143 (5.59%)	4 / 96 (4.17%)	0 / 6 (0.00%)
occurrences (all)	9	6	0
Respiration abnormal			
subjects affected / exposed	7 / 143 (4.90%)	7 / 96 (7.29%)	0 / 6 (0.00%)
occurrences (all)	7	8	0
Asthma			
subjects affected / exposed	5 / 143 (3.50%)	5 / 96 (5.21%)	0 / 6 (0.00%)
occurrences (all)	6	5	0
Dyspnoea			
subjects affected / exposed	4 / 143 (2.80%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	4	6	0
Bronchiectasis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	5 / 143 (3.50%)	2 / 96 (2.08%)	0 / 6 (0.00%)
occurrences (all)	5	2	0
Lower respiratory tract congestion			
subjects affected / exposed	1 / 143 (0.70%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Paranasal sinus hypersecretion			
subjects affected / exposed	4 / 143 (2.80%)	2 / 96 (2.08%)	0 / 6 (0.00%)
occurrences (all)	4	2	0



Rales			
subjects affected / exposed	2 / 143 (1.40%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Rhinitis allergic			
subjects affected / exposed	4 / 143 (2.80%)	4 / 96 (4.17%)	0 / 6 (0.00%)
occurrences (all)	4	4	0
Investigations			
Bacterial test positive			
subjects affected / exposed	30 / 143 (20.98%)	16 / 96 (16.67%)	0 / 6 (0.00%)
occurrences (all)	45	46	0
Alanine aminotransferase increased			
subjects affected / exposed	22 / 143 (15.38%)	21 / 96 (21.88%)	0 / 6 (0.00%)
occurrences (all)	27	26	0
Aspartate aminotransferase increased			
subjects affected / exposed	17 / 143 (11.89%)	13 / 96 (13.54%)	0 / 6 (0.00%)
occurrences (all)	22	16	0
Pseudomonas test positive			
subjects affected / exposed	10 / 143 (6.99%)	3 / 96 (3.13%)	0 / 6 (0.00%)
occurrences (all)	10	6	0
Pulmonary function test decreased			
subjects affected / exposed	8 / 143 (5.59%)	11 / 96 (11.46%)	0 / 6 (0.00%)
occurrences (all)	9	11	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	6 / 143 (4.20%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	6	7	0
Forced expiratory volume decreased			
subjects affected / exposed	6 / 143 (4.20%)	13 / 96 (13.54%)	0 / 6 (0.00%)
occurrences (all)	8	16	0
International normalised ratio increased			
subjects affected / exposed	4 / 143 (2.80%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	5	6	0
Prothrombin time prolonged			
subjects affected / exposed	3 / 143 (2.10%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	4	7	0
Weight decreased			

subjects affected / exposed occurrences (all)	1 / 143 (0.70%) 1	5 / 96 (5.21%) 5	0 / 6 (0.00%) 0
Pulmonary imaging procedure abnormal subjects affected / exposed occurrences (all)	0 / 143 (0.00%) 0	0 / 96 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications Ligament sprain subjects affected / exposed occurrences (all)	4 / 143 (2.80%) 4	2 / 96 (2.08%) 2	0 / 6 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	29 / 143 (20.28%) 43	26 / 96 (27.08%) 36	0 / 6 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	6 / 143 (4.20%) 7	5 / 96 (5.21%) 6	0 / 6 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	12 / 143 (8.39%) 17	4 / 96 (4.17%) 5	0 / 6 (0.00%) 0
Eye disorders Eyelid oedema subjects affected / exposed occurrences (all)	0 / 143 (0.00%) 0	0 / 96 (0.00%) 0	0 / 6 (0.00%) 0
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)	30 / 143 (20.98%) 36	15 / 96 (15.63%) 18	0 / 6 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	22 / 143 (15.38%) 38	20 / 96 (20.83%) 30	0 / 6 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	17 / 143 (11.89%) 23	19 / 96 (19.79%) 24	0 / 6 (0.00%) 0
Diarrhoea			

subjects affected / exposed	16 / 143 (11.19%)	8 / 96 (8.33%)	0 / 6 (0.00%)
occurrences (all)	16	10	0
Nausea			
subjects affected / exposed	13 / 143 (9.09%)	11 / 96 (11.46%)	0 / 6 (0.00%)
occurrences (all)	15	15	0
Constipation			
subjects affected / exposed	11 / 143 (7.69%)	11 / 96 (11.46%)	0 / 6 (0.00%)
occurrences (all)	13	14	0
Flatulence			
subjects affected / exposed	4 / 143 (2.80%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	4	8	0
Dyspepsia			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	0 / 143 (0.00%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	1 / 143 (0.70%)	0 / 96 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	10 / 143 (6.99%)	10 / 96 (10.42%)	0 / 6 (0.00%)
occurrences (all)	12	11	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	5 / 143 (3.50%)	5 / 96 (5.21%)	0 / 6 (0.00%)
occurrences (all)	6	5	0
Infections and infestations			
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	59 / 143 (41.26%)	34 / 96 (35.42%)	0 / 6 (0.00%)
occurrences (all)	115	70	0
Upper respiratory tract infection			
subjects affected / exposed	36 / 143 (25.17%)	13 / 96 (13.54%)	0 / 6 (0.00%)
occurrences (all)	52	21	0

Nasopharyngitis			
subjects affected / exposed	21 / 143 (14.69%)	16 / 96 (16.67%)	0 / 6 (0.00%)
occurrences (all)	34	29	0
Viral upper respiratory tract infection			
subjects affected / exposed	21 / 143 (14.69%)	14 / 96 (14.58%)	0 / 6 (0.00%)
occurrences (all)	28	20	0
Sinusitis			
subjects affected / exposed	17 / 143 (11.89%)	8 / 96 (8.33%)	0 / 6 (0.00%)
occurrences (all)	19	9	0
Otitis media			
subjects affected / exposed	13 / 143 (9.09%)	8 / 96 (8.33%)	0 / 6 (0.00%)
occurrences (all)	13	10	0
Pharyngitis streptococcal			
subjects affected / exposed	12 / 143 (8.39%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	23	6	0
Bacterial disease carrier			
subjects affected / exposed	11 / 143 (7.69%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	15	8	0
Influenza			
subjects affected / exposed	11 / 143 (7.69%)	6 / 96 (6.25%)	0 / 6 (0.00%)
occurrences (all)	16	7	0
Ear infection			
subjects affected / exposed	9 / 143 (6.29%)	7 / 96 (7.29%)	0 / 6 (0.00%)
occurrences (all)	10	10	0
Rhinitis			
subjects affected / exposed	9 / 143 (6.29%)	7 / 96 (7.29%)	0 / 6 (0.00%)
occurrences (all)	19	10	0
Upper respiratory tract infection bacterial			
subjects affected / exposed	8 / 143 (5.59%)	1 / 96 (1.04%)	0 / 6 (0.00%)
occurrences (all)	9	1	0
Bronchitis			
subjects affected / exposed	7 / 143 (4.90%)	7 / 96 (7.29%)	0 / 6 (0.00%)
occurrences (all)	10	9	0
Pharyngitis			

subjects affected / exposed occurrences (all)	5 / 143 (3.50%) 5	7 / 96 (7.29%) 12	0 / 6 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	7 / 143 (4.90%) 8	4 / 96 (4.17%) 4	0 / 6 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	2 / 143 (1.40%) 2	0 / 96 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	3 / 143 (2.10%) 5	1 / 96 (1.04%) 1	0 / 6 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	3 / 143 (2.10%) 5	6 / 96 (6.25%) 6	0 / 6 (0.00%) 0
Glucose tolerance impaired subjects affected / exposed occurrences (all)	1 / 143 (0.70%) 1	1 / 96 (1.04%) 1	0 / 6 (0.00%) 0

<b>Non-serious adverse events</b>	Treatment Period 2: LUM/IVA		
Total subjects affected by non-serious adverse events subjects affected / exposed	9 / 10 (90.00%)		
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Fatigue subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Chest pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		

Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	3		
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Sputum increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Sinus congestion			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Nasal polyps			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Haemoptysis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Respiration abnormal			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Asthma			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Bronchiectasis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Epistaxis			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Lower respiratory tract congestion			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Paranasal sinus hypersecretion			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Rales			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Rhinitis allergic			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Investigations			
Bacterial test positive			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pseudomonas test positive			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pulmonary function test decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Forced expiratory volume decreased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
International normalised ratio increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Prothrombin time prolonged			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Pulmonary imaging procedure abnormal			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		



Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Eye disorders Eyelid oedema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)  Abdominal pain upper subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Constipation subjects affected / exposed occurrences (all)  Flatulence subjects affected / exposed occurrences (all)  Dyspepsia subjects affected / exposed occurrences (all)  Gastritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  1 / 10 (10.00%) 2  1 / 10 (10.00%) 2  1 / 10 (10.00%) 1  1 / 10 (10.00%) 1  0 / 10 (0.00%) 0  1 / 10 (10.00%) 1  1 / 10 (10.00%) 1		
Hepatobiliary disorders			

Hepatomegaly subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Infections and infestations Infective pulmonary exacerbation of cystic fibrosis subjects affected / exposed occurrences (all)  Upper respiratory tract infection subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Viral upper respiratory tract infection subjects affected / exposed occurrences (all)  Sinusitis subjects affected / exposed occurrences (all)  Otitis media subjects affected / exposed occurrences (all)  Pharyngitis streptococcal subjects affected / exposed occurrences (all)  Bacterial disease carrier subjects affected / exposed occurrences (all)	4 / 10 (40.00%) 6  0 / 10 (0.00%) 0  3 / 10 (30.00%) 3  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  2 / 10 (20.00%) 2		

Influenza			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	6 / 10 (60.00%)		
occurrences (all)	11		
Upper respiratory tract infection bacterial			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Oral fungal infection			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Glucose tolerance impaired			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 September 2015	Amended to assess post-dose spirometry.
30 November 2017	Amended to add Treatment Period 2 to assess long-term safety of LUM/IVA in subjects who completed 96 weeks of LUM/IVA treatment in Treatment Period 1.
16 May 2019	Amended to extend Treatment Cohort Period 2 for up to an additional 96 weeks (up to a total of 264 weeks of treatment).

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported